hydroxychloroquine has been researched along with interleukin-8 in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alarcón, GS; Dang, N; González, EB; Liu, J; Martinez-Martinez, LA; McGwin, G; Papalardo, E; Pierangeli, SS; Reveille, JD; Seif, AM; Vilá, LM; Willis, R | 1 |
| Abramo, C; Almeida, CS; Bonfante, HL; Grunewald, STF; Levy, RA; Teixeira, HC | 1 |
| Bagalà, A; Bartiromo, M; Bartoloni, A; Borchi, B; Botta, A; Bresci, S; Cavallo, A; Cirami, C; Cutruzzulà, R; Larti, A; Lugli, G; Tilli, M; Vaglio, A; Xhaferi, B | 1 |
| Ashton, NJ; Blennow, K; Caruso, A; Castelli, F; Comelli, A; Focà, E; Gasparotti, R; Gazzina, S; Leonardi, M; Masciocchi, S; Nocivelli, S; Odolini, S; Padovani, A; Pasolini, MP; Pezzini, A; Pilotto, A; Volonghi, I; Zetterberg, H | 1 |
| Arbustini, E; Bergomi, P; Bozzini, S; Cavagna, L; Colombo, R; Corsico, AG; Cova, E; D'Amato, M; Di Toro, A; Fossali, T; Frangipane, V; Lettieri, S; Lilleri, D; Meloni, F; Mojoli, F; Morosini, M; Ottolina, D; Pandolfi, L; Percivalle, E; Saracino, L; Tomaselli, S; Urtis, M | 1 |
| Bellavita, G; Bonzi, L; Buoite Stella, A; Cecotti, L; D Acunto, L; Fabris, M; Furlanis, G; Manganotti, P; Pesavento, V; Sartori, A; Tommasini, V | 1 |
| Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mansour, MMF; Mino, R; Miyagi, T; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Wakiya, R | 1 |
| Dobashi, H; Kadowaki, N; Kameda, T; Kato, M; Mino, R; Miyagi, T; Miyatake, N; Mizusaki, M; Nakashima, S; Shimada, H; Sugihara, K; Ueeda, K; Wakiya, R | 1 |
8 other study(ies) available for hydroxychloroquine and interleukin-8
| Article | Year |
|---|---|
Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort.
Topics: Adolescent; Adult; Antirheumatic Agents; Biomarkers; CD40 Ligand; Chemokine CCL2; Chemokine CXCL10; Cohort Studies; Cytokines; Female; Humans; Hydroxychloroquine; Interferon-alpha; Interleukin-1beta; Interleukin-6; Interleukin-8; Lupus Erythematosus, Systemic; Male; Middle Aged; Severity of Illness Index; Statistics, Nonparametric; Tumor Necrosis Factor-alpha; United States; Young Adult | 2012 |
CCL2, CXCL8, CXCL9 and CXCL10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees.
Topics: Age Factors; Aged; Aging; Antirheumatic Agents; Biomarkers; Case-Control Studies; Chemokine CCL2; Chemokine CXCL10; Chemokine CXCL9; Female; Humans; Hydroxychloroquine; Interleukin-8; Male; Middle Aged; Osteoarthritis, Knee; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).
Topics: Adult; Antiviral Agents; Betacoronavirus; C-Reactive Protein; Ciliopathies; Cobicistat; Common Cold; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Deprescriptions; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Fatigue; Female; Glucocorticoids; Graft Rejection; Humans; Hydroxychloroquine; Immunocompromised Host; Immunosuppressive Agents; Interleukin-10; Interleukin-1beta; Interleukin-6; Interleukin-8; Kidney Diseases, Cystic; Kidney Failure, Chronic; Kidney Transplantation; Leber Congenital Amaurosis; Lopinavir; Methylprednisolone; Optic Atrophies, Hereditary; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Severity of Illness Index; Tacrolimus | 2020 |
Steroid-Responsive Encephalitis in Coronavirus Disease 2019.
Topics: Akinetic Mutism; Antiviral Agents; beta 2-Microglobulin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Electroencephalography; Encephalitis; Glucocorticoids; Humans; Hydroxychloroquine; Interleukin-6; Interleukin-8; Lopinavir; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Treatment Outcome; Tumor Necrosis Factor-alpha | 2020 |
Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Bronchoalveolar Lavage; Bronchoalveolar Lavage Fluid; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Female; Humans; Hydroxychloroquine; Inflammation; Intensive Care Units; Interleukin-10; Interleukin-6; Interleukin-8; Italy; Leukocytes; Leukocytes, Mononuclear; Lopinavir; Lung; Lymphocytes; Macrophages, Alveolar; Male; Microscopy, Electron, Transmission; Middle Aged; Neutrophils; Pandemics; Pneumonia, Viral; Prognosis; Prospective Studies; Respiration, Artificial; Ritonavir; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Survival Rate; Virion | 2020 |
Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients.
Topics: Action Potentials; Acute Disease; Aged; Anti-Bacterial Agents; Biomarkers; Convalescence; COVID-19; COVID-19 Drug Treatment; Darunavir; Drug Combinations; Guillain-Barre Syndrome; Humans; Hydroxychloroquine; Immunoglobulins, Intravenous; Interleukin-6; Interleukin-8; Lopinavir; Male; Neural Conduction; Peripheral Nervous System; Prognosis; Respiratory Insufficiency; Ritonavir; SARS-CoV-2 | 2021 |
Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus.
Topics: Chemokine CCL3; Cytokines; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Interleukin-6; Interleukin-8; Lupus Erythematosus, Systemic; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2022 |
Supplemental hydroxychloroquine therapy regulates adipokines in patients with systemic lupus erythematosus with stable disease.
Topics: Adipokines; Adiponectin; Adult; Antibodies, Antinuclear; Antirheumatic Agents; Atherosclerosis; Cytokines; Estrogens; Female; Humans; Hydroxychloroquine; Interleukin 1 Receptor Antagonist Protein; Interleukin-8; Leptin; Lipids; Lupus Erythematosus, Systemic; Male; Middle Aged; Resistin; Tumor Necrosis Factor-alpha | 2022 |